Skip to content

Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) for Localized Prostate Cancer

Comparative Effectiveness Study of Various Treatments for Localized Prostate Cancer

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01326286
Acronym
CEASAR
Enrollment
3265
Registered
2011-03-30
Start date
2011-03-31
Completion date
2018-09-30
Last updated
2018-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

Comparative Effectiveness Research, Prostatectomy, radiotherapy, quality of life

Brief summary

This study will primarily compare the effectiveness of surgery and radiation for localized prostate cancer, the most common male cancer. It will focus on modern technologies and control for differences in patients and treatments that may affect both cancer-related and patient-reported outcomes (such as impotence and incontinence). By figuring out what treatments work best, in which patients and in whose hands, it will help men with prostate cancer make better decisions regarding their care.

Detailed description

Prostate cancer is the most common solid tumor and the second leading cause of cancer death among American men. While surgery, radiation and observation have all been deemed appropriate for newly diagnosed men, tremendous uncertainty remains regarding the optimal treatment. AHRQ's 2008 evidence report on the comparative effectiveness of therapies for localized prostate cancer concluded that no one therapy can be considered the preferred treatment for localized prostate cancer due to the limitations in the body of evidence as well as the likely tradeoffs an individual patient must make between estimated treatment effectiveness, necessity and adverse effects. The existing literature is limited by its focus on older therapeutic modalities and failure to control for individual patient characteristics and provider/hospital characteristics that may influence outcomes (quality of care). To fill these evidence gaps, we propose to expand a network of state tumor registries and a national observational disease registry to establish a new population-based cohort of men newly diagnosed with localized prostate cancer. We will prospectively measure key patient-reported outcomes, such as health-related quality of life and side-effects of therapy at diagnosis and 6 and 12 months later. We will also collect detailed medical record information, including clinical data, technical details of the interventions, complications, short-term cancer recurrence rates, and quality-of-care indicators. By using this approach, we will overcome limitations of the extant literature and achieve the following specific aims: 1. To compare the effectiveness of contemporary surgical and radiation techniques for localized prostate cancer in the cohort described above in terms of the 6- and 12-month patient-reported outcomes, side-effects and complications of treatment. 2. To identify patient level characteristics that may influence comparative effectiveness. 3. To assess how the comparative effectiveness of the various therapies varies by quality of care received.

Interventions

None listed

Sponsors

Patient-Centered Outcomes Research Institute
CollaboratorOTHER
Agency for Healthcare Research and Quality (AHRQ)
CollaboratorFED
Louisiana State University Health Sciences Center in New Orleans
CollaboratorOTHER
University of California, Irvine
CollaboratorOTHER
University of California, San Francisco
CollaboratorOTHER
University of Southern California
CollaboratorOTHER
M.D. Anderson Cancer Center
CollaboratorOTHER
University of Utah
CollaboratorOTHER
Emory University
CollaboratorOTHER
Rutgers Cancer Institute of New Jersey
CollaboratorOTHER
Vanderbilt University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
18 Years to 79 Years
Healthy volunteers
No

Inclusion criteria

* Pathologic diagnosis of adenocarcinoma of the prostate * Clinically localized stage * PSA \<50ng/ml * age 18-79

Exclusion criteria

* diagnosis of other malignancy (excluding squamous or basal cell carcinoma of the skin) within 3 years of diagnosis of prostate cancer * age 80 or greater * clinically locally advanced or metastatic disease * PSA equal to or greater than 50 ng/ml * pathologic diagnosis of prostate cancer greater than 6 months prior to baseline recruitment interview

Design outcomes

Primary

MeasureTime frameDescription
Disease-Specific Health-Related Quality of Life (EPIC)12, 24 and 60 months after enrollmentSexual, urinary, bowel and hormonal function and bother subscores will be assessed

Secondary

MeasureTime frameDescription
cancer-free survival6 and 12 months after enrollmentassessed using PSA levels obtained from medical record review
Complications of treatment6- and 12-months after enrollmentdata collected from patient report and medical record review
General Health-Related Quality of Life (SF-12)6- and 12-months after enrollment

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026